BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Radiology (2004) 77, 821-830
© 2004 British Institute of Radiology
doi: 10.1259/bjr/19527646
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fenchel, S
Right arrow Articles by Merkle, E M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fenchel, S
Right arrow Articles by Merkle, E M

Effect of iodine concentration of contrast media on contrast enhancement in multislice CT of the pancreas

S Fenchel, MD1,2, T R Fleiter, MD1,2, A J Aschoff, MD1, R van Gessel, PhD3, H-J Brambs, MD1 and E M Merkle, MD1,2

1 Department of Radiology, University of Ulm, Steinhoevelstr. 9, 89075 Ulm, Germany, 2 Department of Radiology, University Hospitals of Cleveland/Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA and 3 Bracco Altana Pharma GmbH, Max-Stromeyer- Str. 57, 78467 Konstanz, Germany



View larger version (134K):

[in a new window]
  		Figure 1. 63-year-old woman with carcinoma of the pancreatic head and dilation of the bile ducts and the pancreatic duct after injection of Iomeprol 400: (a) arterial phase scan, (b) portal venous phase scan. 66-year-old man with carcinoma of the pancreatic body, who received Iomeprol 300: (c) arterial phase scan, (d) portal venous phase scan. The higher arterial phase contrast enhancement with Iomeprol 400 (a) compared with Iomeprol 300 (c) for the large and small arteries, the pancreas and the kidneys as well as the higher portal venous phase enhancement for the pancreas and portal vein with Iomeprol 400 (b) compared with Iomeprol 300 (d) are demonstrated.

 



View larger version (141K):

[in a new window]
  		Figure 2. 58-year-old woman after resection of the pancreatic tail because of a carcinoid tumour 3 years previously. The patient received Iomeprol 400: (a, b) arterial phase, (c, d) portal venous phase. 51-year-old man after Whipple procedure, who received Iomeprol 300: arterial phase (e, f), portal venous phase (g, h). Figures 2a–dGo show the higher arterial and portal venous phase contrast enhancement of the pancreatic head and body with Iomeprol 400 compared with the pancreatic body and tail of the patient in Figures 2e–hGo who had received Iomeprol 300. Additionally, the higher arterial phase contrast enhancement of the large and small arteries, the kidneys and the small intestine and the higher portal venous contrast enhancement of the portal vein and the small intestine with Iomeprol 400 (a–d) compared with Iomeprol 300 (e–h) are demonstrated.

 


View larger version (56K):

[in a new window]
  		Figure 3. 34-year-old woman with chronic pancreatitis after injection of Iomeprol 400: (a) arterial phase, (b) portal venous phase. Figure 3aGo demonstrates the higher arterial phase contrast enhancement of the spleen with Iomeprol 400 compared with Iomeprol 300 (Figures 2e and fGo). Figure 3bGo shows the higher portal venous phase contrast enhancement for the portal vein with Iomeprol 400 compared with Iomeprol 300 (Figures 2g and hGo).

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2004 by the British Institute of Radiology.